Section: 
School of pharmacotherapy
School of pharmacotherapyThe place and role of the anticongestive agent alpha-adrenomimetics in the complex therapy of acute infectious rhinitis
A. A. Krivopalov (1), S. V. Ryazantsev (2), V. I. Popadyuk (3), A. M. Korkmazov (4), B. V. Turieva (5), A. A. Aslambekova (6)
(1), (2), (5), (6) Saint Petersburg Research Institute of Ear, Throat, Nose and Speech, Saint Petersburg, 190013, Russian Federation, (1), (2) Mechnikov North-Western State Medical University, Saint Petersburg, 191015, Russian Federation, (3) Patrice Lumumba Peoples' Friendship University of Russia Medical Institute, Moscow, 117198, Russian Federation, (4) South Ural State Medical University, Chelyabinsk, 454092, Russian Federation
UDK: УДК 616.211-002.1-08-039.73:615.225.1
DOI: https://doi.org/10.18692/1810-4800-2025-2-112-125
ABSTRACT
Abstract. Conduction. Of the entire nosological nomenclature of acute respiratory infections (ARI) of the upper respiratory tract (VDP) included in the ICD-10 under the codes from J00 to J06, acute nasopharyngitis (acute rhinitis) is the most in demand in the study of etiopathogenesis and improvement of medical aids, as the most common disease included in the Guinness Book of Records, the main causes of which are there are viral and bacterial infections. According to the Ministry of Health of the Russian Federation, every year there is an increase in cases of infectious diseases, including acute rhinitis, which leads to a solution to the issue of improving effective and safe therapy. The aim — is to increase the effectiveness of treatment of patients with acute nasopharyngitis by including short courses of modern alpha-adrenomimetics in complex therapy and assessing tolerability. Patients and methods. A comparative prospective observational study was conducted on the basis of the Federal State Budgetary Institution of St. Petersburg "Research Institute of ENT" of the Ministry of Health of the Russian Federation to evaluate the effectiveness and tolerability of the drug „Rinomaris Advance®“ in patients with acute nasopharyngitis 79 patients aged 18 to 70 years with a diagnosis of acute nasopharyngitis were examined. Patients received the drug "Rinomaris Advance®" as part of complex therapy 2 times a day. Results. During the study, it was found that the drug already on the 3rd day of treatment minimizes the severity of symptoms in acute nasopharyngitis, such as: nasal congestion, discharge from the nasal cavity, mucus trickling down the back wall of the pharynx, sneezing, itching in the nasal cavity, and patients noted an improvement in sleep quality, lack of awakenings. Conclusions. The combined preparation consisting of xylometazoline 0.05%, sodium hyaluronate 0.01%, as well as excipients: purified seawater, potassium dihydrophosphate, purified water (Rinomaris Advance®) showed high therapeutic efficacy, tolerability and safety in the treatment of acute nasopharyngitis.
Publication date:
21.04.2025
Keywords:
acute nasopharyngitis, combined drug, decongestants, nasal obstruction, xylometazoline For citation:
Krivopalov A. A., Ryazantsev S. V., Popadyuk V. I., Korkmazov A. M., Turieva B. V., Aslambekova A. A. The place and role of the anticongestive agent alpha-adrenomimetics in the complex therapy of acute infectious rhinitis. Russian Otorhinolaryngology. 2025;24(2):112-125. (In Russ.) https://doi.org/10.18692/1810-4800-2025-2-112-125